Ocular Therapeutix, Inc.
OCUL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,150,023 | $1,601,678 | $1,241,680 | $1,434,882 |
| - Cash | $344,772 | $391,134 | $349,681 | $392,102 |
| + Debt | $77,008 | $76,939 | $76,224 | $75,783 |
| Enterprise Value | $1,882,259 | $1,287,483 | $968,223 | $1,118,563 |
| Revenue | $14,544 | $13,459 | $10,698 | $17,082 |
| % Growth | 8.1% | 25.8% | -37.4% | – |
| Gross Profit | $12,770 | $11,515 | $9,436 | $15,852 |
| % Margin | 87.8% | 85.6% | 88.2% | 92.8% |
| EBITDA | -$65,344 | -$63,772 | -$60,088 | -$44,331 |
| % Margin | -449.3% | -473.8% | -561.7% | -259.5% |
| Net Income | -$69,418 | -$67,814 | -$64,053 | -$48,388 |
| % Margin | -477.3% | -503.9% | -598.7% | -283.3% |
| EPS Diluted | -0.38 | -0.39 | -0.38 | -0.29 |
| % Growth | 2.6% | -2.6% | -31% | – |
| Operating Cash Flow | -$50,725 | -$55,238 | -$44,671 | -$39,429 |
| Capital Expenditures | -$5,993 | -$1,245 | -$1,933 | -$202 |
| Free Cash Flow | -$56,718 | -$56,483 | -$46,604 | -$39,631 |